Radar snapshot

37
Ingredients tracked
8
Fringe trends
5
Segments

Highest velocity signals this month

Methylene blue: syndicated coverage of serotonin-toxicity risk widens awareness. A liability watch, not an opportunity.
Amare Global: the FTC escalates to a contempt motion over repeat health claims.
Postbiotics: new human trials move the category from pipeline to enrollment.
Creatine (midlife women): a new RCT adds population-specific cognition and strength data.

Current alerts

RedMoringa Salmonella outbreak, at least four brands
RedFTC contempt motion against Amare Global
AmberNMN lawful but NDIN still required
AmberMethylene blue biohacker use, no safety data
AmberKids magnesium gummies with undeclared melatonin
SignalDSHEA disclaimer enforcement discretion
SignalPostbiotics: shelf-stable formats, human trials enrolling

This edition

4 radar position changes: NMN, creatine (midlife women), methylene blue, moringa
0 new ingredients. Single-brand trial programs did not meet the bar for a category signal
1 red alert retired: Xlear v. FTC, dismissed July 27, 2026. Moringa outbreak and Amare alerts escalated